الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 97 |  |  |
| | | from | 97 | | |
Abstract
A harmful iatrogenic side effect of inducing ovulation is ovarian hyperstimulation syndrome (OHSS). Although it is a rare or uncommon disorder, it might be challenging to determine its real occurrence since there isn’t a clear agreed definition. The incidence varies depending on how serious a case is, from 33 percent in mild instances to 3-6 percent in moderate situations, and just 1-2 percent in severe cases. These extreme instances are potentially lethal, life-threatening illnesses. Additionally, since the pathophysiology of this disorder is not entirely understood, it is easier to find preventative and therapeutic approaches.
The illness generally typically manifests either during early pregnancy, 9 or more days after hCG injection associated to pregnancy induced hCG production (late onset), or up to 8 days following hCG administration in susceptible individuals. Pre-ovulatory ovarian response indices may, to some degree, predict early OHSS, allowing for the implementation of preventative measures like cancellation. Since late OHSS and pre-ovulatory ovarian response are not significantly correlated, it is difficult for doctors to pinpoint the cycles during which it is most likely to occur.
Vascular endothelial growth factor, among these mediators, is the most significant (VEGF). A vasoactive mediator called VEGF makes capillaries more permeable. It has been discovered that VEGF is expressed in human ovaries, and that it is expressed more strongly in the granulosa cells. Human chorionic gonadotropin (hCG) treatment has been shown to raise VEGF mRNA levels in granulosa cells, and higher quantities of secreted proteins have been seen in serum, plasma, and peritoneal fluids in women at risk or with OHSS. By interacting with its VEGF receptor 2, VEGF promotes the growth of new blood vessels and vascular hyperpermeability (VEGFR2). Angotensin II, interleukin-6, insulin-like growth factor 1, IGF-1, epidermal growth factor, transforming growth factor a and b, basic fibroblast growth factor, platelet-driven growth factor interleukin 1b, and other substances that can act directly or indirectly through VEGF are other substances that have been implicated.
Although there is no known treatment for this illness, prevention is regarded as a crucial and important problem.
The purpose of our study is to compare the early intake of cabergoline (starting at the time of estradiol peak and optimal follicular count until ovum retrieval and continued for 8 days after ovum retrieval) to the known standard intake (on the day of ovum retrieval for 8 days after) in preventing the development of OHSS in high risk patients undergoing GnRH Agonist down regulation ICSI cycles.